Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide synthase
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting the motor system. Although the etiology of the disease is not fully understood, microglial activation and neuroinflammation are thought to play a role in disease progression. METHODS: We examined the immunohistochemical expression of two markers of microglial phenotype, the arginine-metabolizing enzymes inducible nitric oxide synthase (iNOS) and arginase1 (Arg1), in the spinal cord of a mouse model carrying an ALS-linked mutant human superoxide dismutase transgene (SOD1(G93A)) and in non-transgenic wild-type (WT) mice. Immunolabeling for iNOS and Arg1 was evaluated throughout disease progression (6 to 25 weeks), and correlated with body weight, stride pattern, wire hang duration and ubiquitin pathology. For microglia and motor neuron counts at each time point, SOD1(G93A) and WT animals were compared using an independent samples t-test. A Welch t-test correction was applied if Levene's test showed that the variance in WT and SOD1G93A measurements was substantially different. RESULTS: Disease onset, measured as the earliest change in functional parameters compared to non-transgenic WT mice, occurred at 14 weeks of age in SOD1(G93A) mice. The ventral horn of the SOD1(G93A) spinal cord contained more microglia than WT from 14 weeks onwards. In SOD1(G93A) mice, Arg1-positive and iNOS-positive microglia increased 18-fold and 7-fold, respectively, between 10 and 25 weeks of age (endpoint) in the lumbar spinal cord, while no increase was observed in WT mice. An increasing trend of Arg1- and iNOS-expressing microglia was observed in the cervical spinal cords of SOD1(G93A) mice. Additionally, Arg1-negative motor neurons appeared to selectively decline in the spinal cord of SOD1(G93A) mice, suggesting that Arg1 may have a neuroprotective function. CONCLUSIONS: This study suggests that the increase in spinal cord microglia occurs around and after disease onset and is preceded by cellular pathology. The results show that Arg1 and iNOS, thought to have opposing inflammatory properties, are upregulated in microglia during disease progression and that Arg1 in motor neurons may confer protection from disease processes. Further understanding of the neuroinflammatory response, and the Arg1/iNOS balance in motor neurons, may provide suitable therapeutic targets for ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Imai, Y., Ibata, I., Ito, D., Ohsawa, K., & Kohsaka, S. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1112 · Cited by 872 · cited 1×
“Spinal cord microglia were identified either by anti-Iba1 immunolabeling or by TL labeling [22,23].”
MethodCurrent hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703 · cited 1×
“Although ALS is characterized primarily by selective degeneration of motor neurons, it is increasingly regarded as a complex multifactorial disease involving dysregulation of cellular processes affecting both neurons and glial cells [5-7].”
BackgroundMolecular pathways of motor neuron injury in amyotrophic lateral sclerosis
Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., & Shaw, P. J. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.152 · Cited by 615 · cited 1×
“Although ALS is characterized primarily by selective degeneration of motor neurons, it is increasingly regarded as a complex multifactorial disease involving dysregulation of cellular processes affecting both neurons and glial cells [5-7].”
BackgroundBaek, K. J., Thiel, B. A., Lucas, S., & Stuehr, D. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36901-7 · Cited by 389 · cited 1×
“The decreasing level of Arg1 and increasing level of iNOS may disrupt the normal balance of arginine metabolism, with SOD1 motor neurons skewed towards iNOS-mediated production of NO rather than Arg1-mediated production of ornithine [40-44].”
BackgroundMicroglia in ALS: The Good, The Bad, and The Resting
Henkel, J. S., Beers, D. R., Zhao, W., & Appel, S. H. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9171-5 · Cited by 353 · cited 2×
“The increase in the number of Arg1-expressing lumbar microglia as disease progresses may be an attempt to limit tissue damage and neuronal degeneration caused by disease processes [20,34], but these results did not appear to be in line with the widelyperceived switch from an M2 to an M1 phenotype in SOD1 mice [12,13].”
BackgroundResultHerbert, R. P., Harris, J., Chong, K. P., Chapman, J., West, A. K., & Chuah, M. I. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-109 · Cited by 69
Self-citationGowing, G., Lalancette-Hébert, M., Audet, J.-N., Dequen, F., & Julien, J.-P. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.021 · Cited by 53 · cited 1×
“Subsequently during the rapidly-progressing disease phase, M2 markers were downregulated and the M1 markers tumor necrosis factor α, NOX2 and IL-6 became more prominent [12,13,18,32,35,36].”
Background
Cited by
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches
Geloso, M. C., Corvino, V., Marchese, E., Serrano, A., Michetti, F., & D’Ambrosi, N. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00242 · Cited by 242
“In line with this results, an increased expression of both iNOS (M1 marker) and arginase 1 (Arg1; M2 marker) has been shown to parallel the generalized increase of activated microglia in SOD1G93A mice (Lewis et al., 2014).”
ResultKobashi, S., Terashima, T., Katagi, M., Nakae, Y., Okano, J., Suzuki, Y., Urushitani, M., & Kojima, H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.004 · Cited by 186
Trias, E., Beilby, P. R., Kovacs, M., Ibarburu, S., Varela, V., Barreto-Núñez, R., Bradford, S. C., Beckman, J. S., & Barbeito, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00042 · Cited by 85
Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis
Potenza, R. L., De Simone, R., Armida, M., Mazziotti, V., Pèzzola, A., Popoli, P., & Minghetti, L. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0462-2 · Cited by 69
Metadata
- Authors
- Lewis, K. E., Rasmussen, A. L., Bennett, W., King, A., West, A. K., Chung, R. S., & Chuah, M. I.
- Venue
- Journal of Neuroinflammation
- Published
- 2014-03-23
- Volume
- 11
- Issue
- 1
- Pages
- 55-55
- ISSN
- 1742-2094 (ISSN-L)
- OpenAlex
- W2161163550
- Cited by
- 73
- References
- 8
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide synthase. https://app.cochat.ai/papers/10.1186/1742-2094-11-55
- The paper
- Lewis, K. E., Rasmussen, A. L., Bennett, W., King, A., West, A. K., Chung, R. S., & Chuah, M. I. (2014). Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide synthase. Journal of Neuroinflammation. https://doi.org/10.1186/1742-2094-11-55
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.